Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/8/2020
SIETES contiene 93083 citas

 
 
 1 a 20 de 340 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Parsons L. Novavax reports promising phase 1 results for coronavirus vaccine. PMLiVE 2020:5 de agosto. [Ref.ID 103702]
4. Cita con resumen
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020:20 de julio. [Ref.ID 103690]
5. Cita con resumen
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough P, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, et al. for the mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med 2020:14 de julio. [Ref.ID 103684]
6. Cita con resumen
Mullard A. COVID-19 vaccine development pipeline gears up. Lancet 2020:6 de junio. [Ref.ID 103658]
7. Cita con resumen
PMG Group. Imperial College London pledges low-cost access to COVID-19 vaccine. PMLiVE 2020:8 de junio. [Ref.ID 103657]
9. Cita con resumen
Taylor P. Novavax COVID-19 vaccine bags record $384m funding from CEPI. PMLiVE 2020:12 de mayo. [Ref.ID 103623]
10. Cita con resumen
Corbella J. La primera vacuna de la Covid ensayada en personas muestra eficacia. La Vanguardia 2020:19 de mayo. [Ref.ID 103619]
12.Enlace a cita original Cita con resumen
PM Group. Developing a COVID-19 vaccine. PMLiVE 2020:28 de abril. [Ref.ID 103606]
13.Enlace a cita original Cita con resumen
PMG Group. Moderna submits application to advance coronavirus vaccine testing. PMLiVE 2020:28 de abril. [Ref.ID 103605]
14.Enlace a cita original Cita con resumen
Abrams DI, Guzmán M. Can cannabis cure cancer?1. JAMA Oncology 2020:1. [Ref.ID 103508]
15.Enlace a cita original Cita con resumen
Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G, CANALS Study Group. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2018;18:febrero. [Ref.ID 102909]
18.Enlace a cita original Cita con resumen
Fuentes Camps I, Rodríguez A, Agustí A. Non-commercial vs. commercial clinical trials: a retrospective study of the applications submitted to a research ethics committee . Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102808]
19.Enlace a cita original Cita con resumen
Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 2018;391:30 de junio. [Ref.ID 102741]
20. Cita con resumen
Desjardins A, Gromeier M, Herndon II JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:12 de juliol. [Ref.ID 102734]
Seleccionar todas
 
 1 a 20 de 340 siguiente >>